A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Charles River Laboratories International, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 16,300 shares of CRL stock, worth $3.19 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
16,300
Previous 21,400 23.83%
Holding current value
$3.19 Million
Previous $4.42 Million 27.38%
% of portfolio
0.01%
Previous 0.01%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$187.96 - $245.29 $958,596 - $1.25 Million
-5,100 Reduced 23.83%
16,300 $3.21 Million
Q2 2024

Aug 14, 2024

SELL
$206.39 - $268.73 $577,892 - $752,444
-2,800 Reduced 11.57%
21,400 $4.42 Million
Q1 2024

May 15, 2024

SELL
$203.52 - $273.43 $305,280 - $410,145
-1,500 Reduced 5.84%
24,200 $6.56 Million
Q4 2023

Feb 14, 2024

SELL
$164.52 - $238.84 $16,452 - $23,884
-100 Reduced 0.39%
25,700 $6.08 Million
Q3 2023

Nov 14, 2023

SELL
$194.44 - $217.61 $544,432 - $609,308
-2,800 Reduced 9.79%
25,800 $5.06 Million
Q2 2023

Aug 14, 2023

SELL
$183.71 - $210.25 $2.06 Million - $2.35 Million
-11,200 Reduced 28.14%
28,600 $6.01 Million
Q1 2023

May 15, 2023

SELL
$191.89 - $259.92 $10.6 Million - $14.4 Million
-55,400 Reduced 58.19%
39,800 $8.03 Million
Q4 2022

Feb 14, 2023

SELL
$197.11 - $250.07 $29.8 Million - $37.8 Million
-151,100 Reduced 61.35%
95,200 $20.7 Million
Q3 2022

Nov 14, 2022

BUY
$182.44 - $250.54 $492,588 - $676,458
2,700 Added 1.11%
246,300 $48.5 Million
Q3 2022

Nov 14, 2022

BUY
$182.44 - $250.54 $492,588 - $676,458
2,700 Added 1.11%
246,300 $48.5 Million
Q2 2022

Aug 15, 2022

BUY
$204.13 - $302.4 $13.1 Million - $19.4 Million
64,300 Added 35.86%
243,600 $52.1 Million
Q1 2022

May 16, 2022

BUY
$255.51 - $362.11 $38.3 Million - $54.2 Million
149,800 Added 507.8%
179,300 $50.9 Million
Q4 2021

Feb 14, 2022

BUY
$351.38 - $448.68 $2.32 Million - $2.96 Million
6,600 Added 28.82%
29,500 $11.1 Million
Q3 2021

Nov 15, 2021

BUY
$372.64 - $458.3 $8.53 Million - $10.5 Million
22,900 New
22,900 $9.45 Million
Q1 2021

May 17, 2021

SELL
$249.67 - $299.48 $2.1 Million - $2.52 Million
-8,400 Closed
0 $0
Q4 2020

Feb 16, 2021

SELL
$222.0 - $252.62 $9.57 Million - $10.9 Million
-43,100 Reduced 83.69%
8,400 $2.1 Million
Q3 2020

Nov 16, 2020

SELL
$175.56 - $226.45 $4.16 Million - $5.37 Million
-23,700 Reduced 31.52%
51,500 $11.7 Million
Q2 2020

Aug 14, 2020

BUY
$118.84 - $189.72 $3.72 Million - $5.94 Million
31,300 Added 71.3%
75,200 $13.1 Million
Q1 2020

May 15, 2020

BUY
$98.9 - $178.34 $4.15 Million - $7.49 Million
42,000 Added 2210.53%
43,900 $5.54 Million
Q4 2019

Feb 14, 2020

SELL
$126.05 - $152.76 $932,770 - $1.13 Million
-7,400 Reduced 79.57%
1,900 $290,000
Q3 2019

Nov 14, 2019

SELL
$125.07 - $143.67 $775,434 - $890,753
-6,200 Reduced 40.0%
9,300 $1.23 Million
Q2 2019

Aug 14, 2019

SELL
$123.4 - $148.55 $2.06 Million - $2.48 Million
-16,700 Reduced 51.86%
15,500 $2.2 Million
Q1 2019

May 15, 2019

SELL
$104.82 - $146.73 $681,330 - $953,744
-6,500 Reduced 16.8%
32,200 $4.68 Million
Q4 2018

Feb 14, 2019

SELL
$105.09 - $137.23 $1.62 Million - $2.12 Million
-15,454 Reduced 28.54%
38,700 $4.38 Million
Q3 2018

Nov 14, 2018

SELL
$112.11 - $134.54 $2.62 Million - $3.15 Million
-23,400 Reduced 30.17%
54,154 $7.29 Million
Q2 2018

Aug 14, 2018

SELL
$102.37 - $117.25 $531,914 - $609,231
-5,196 Reduced 6.28%
77,554 $8.71 Million
Q1 2018

May 15, 2018

BUY
$98.19 - $115.2 $471,312 - $552,960
4,800 Added 6.16%
82,750 $8.83 Million
Q4 2017

Feb 14, 2018

SELL
$100.43 - $118.09 $4.82 Million - $5.67 Million
-48,000 Reduced 38.11%
77,950 $8.53 Million
Q3 2017

Nov 14, 2017

BUY
$96.72 - $109.26 $12.2 Million - $13.8 Million
125,950
125,950 $13.6 Million

Others Institutions Holding CRL

About CHARLES RIVER LABORATORIES INTERNATIONAL, INC.


  • Ticker CRL
  • Exchange NYSE
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 50,863,300
  • Market Cap $9.96B
  • Description
  • Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Ass...
More about CRL
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.